Forskning ved Københavns Universitet - Københavns Universitet

Forside

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. / Lassen, Michael Rud; Gallus, Alexander; Raskob, Gary E; Pineo, Graham; Chen, Dalei; Ramirez, Luz Margarita; ADVANCE-3 Investigators; Duus, Benn Rønnow.

I: New England Journal of Medicine, Bind 363, Nr. 26, 23.12.2010, s. 2487-98.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Lassen, MR, Gallus, A, Raskob, GE, Pineo, G, Chen, D, Ramirez, LM, ADVANCE-3 Investigators & Duus, BR 2010, 'Apixaban versus enoxaparin for thromboprophylaxis after hip replacement', New England Journal of Medicine, bind 363, nr. 26, s. 2487-98. https://doi.org/10.1056/NEJMoa1006885

APA

Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., Ramirez, L. M., ADVANCE-3 Investigators, & Duus, B. R. (2010). Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine, 363(26), 2487-98. https://doi.org/10.1056/NEJMoa1006885

Vancouver

Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM o.a. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine. 2010 dec 23;363(26):2487-98. https://doi.org/10.1056/NEJMoa1006885

Author

Lassen, Michael Rud ; Gallus, Alexander ; Raskob, Gary E ; Pineo, Graham ; Chen, Dalei ; Ramirez, Luz Margarita ; ADVANCE-3 Investigators ; Duus, Benn Rønnow. / Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. I: New England Journal of Medicine. 2010 ; Bind 363, Nr. 26. s. 2487-98.

Bibtex

@article{a76356681d14456eb02525d0ba5808ed,
title = "Apixaban versus enoxaparin for thromboprophylaxis after hip replacement",
abstract = "There are various regimens for thromboprophylaxis after hip replacement. Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some degree. Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use.",
author = "Lassen, {Michael Rud} and Alexander Gallus and Raskob, {Gary E} and Graham Pineo and Dalei Chen and Ramirez, {Luz Margarita} and Lassen, {Michael Rud} and Duus, {Benn R{\o}nnow}",
year = "2010",
month = dec,
day = "23",
doi = "http://dx.doi.org/10.1056/NEJMoa1006885",
language = "English",
volume = "363",
pages = "2487--98",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachusetts Medical Society",
number = "26",

}

RIS

TY - JOUR

T1 - Apixaban versus enoxaparin for thromboprophylaxis after hip replacement

AU - Lassen, Michael Rud

AU - Gallus, Alexander

AU - Raskob, Gary E

AU - Pineo, Graham

AU - Chen, Dalei

AU - Ramirez, Luz Margarita

AU - ADVANCE-3 Investigators

AU - Duus, Benn Rønnow

PY - 2010/12/23

Y1 - 2010/12/23

N2 - There are various regimens for thromboprophylaxis after hip replacement. Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some degree. Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use.

AB - There are various regimens for thromboprophylaxis after hip replacement. Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some degree. Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use.

U2 - http://dx.doi.org/10.1056/NEJMoa1006885

DO - http://dx.doi.org/10.1056/NEJMoa1006885

M3 - Journal article

VL - 363

SP - 2487

EP - 2498

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 26

ER -

ID: 34053104